Skip to main content

Table 3 Predictors for not adhering to ULT

From: Factors associated with initiation and persistence of urate-lowering therapy

   Predictors for not persisting with ULT after 125 daysa (Log)
% with event Univariate odds ratio 95% CI Multivariateb odds ratio 95% CI (with eGFR) Multivariatec odds ratio 95% CI (with renal disease)
Male (ref) 37.47    
Female 36.30 0.95 (0.78–1.16) 0.89 (0.71–1.13) 0.92 (0.75–1.13)
Age, years
 20–49 (ref) 54.29    
 50–59 37.65 0.51 (0.36–0.73) 0.50 (0.31–0.79) 0.54 (0.38–0.77)
 60–69 37.31 0.50 (0.37–0.68) 0.63 (0.42–0.95) 0.58 (0.42–0.80)
 70–79 33.28 0.42 (0.31–0.57) 0.59 (0.39–0.91) 0.51 (0.37–0.71)
 80– 32.55 0.41 (0.30–0.56) 0.70 (0.44–1.11) 0.52 (0.36–0.74)
MCCI
 0 (ref) 43.65    
 1–2 32.67 0.63 (0.51–0.76) 0.75 (0.59–0.96) 0.74 (0.60–0.92)
 >2 30.16 0.56 (0.42–0.73) 0.71 (0.52–0.99) 0.69 (0.51–0.93)
Renal disease
0 (ref) 38.54    
1 29.57 0.67 (0.52–0.86) 0.74 (0.57–0.97)  
eGFR >60 mL/min/1.73 m2 “normal kidney function” (ref) 41.62    
eGFR 60–31 mL/min/1.73 m2 “reduced kidney function” 31.19 0.64 (0.51–0.79)   0.68 (0.53–0.87)
eGFR 30–10 mL/min/1.73 m2 severely reduced kidney function” 28.57 0.56 (0.37–0.85)   0.59 (0.37–0.92)
eGFR <10 mL/min/1.73 m2 “end-stage kidney failure” 25.00 0.47 (0.05–4.51)   0.53 (0.05–5.11)
2011, ref 37.40    
2012 33.87 0.86 (0.69–1.06)   
2013 41.62 1.19 (0.95–1.50)   
  1. ULT urate-lowering treatment, CI confidence interval, eGFR estimated glomerular filtration rate, MCCI metabolic cardiovascular comorbidity index
  2. aDefined as no ULT dispensation 125 days after last dispensation
  3. bAdjusted for sex, age, comorbidities, and eGFR
  4. cAdjusted for sex, age, comorbidities and renal disease